Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | PRKCA | P17252 | 4/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985076 | 1.00 | MAPT (0.57) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9804875 | 0.88 | LMNA (0.51) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL6288645 | 0.85 | FAAH (0.45) | MAPTMAPK1LMNAKDM4EDUSP3 | |
| SCHEMBL1857261 | 0.79 | MAPT (0.54) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL10539866 | 0.79 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL2727007 | 0.79 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL460365 | 0.79 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL8440393 | 0.79 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL30932044 | 0.79 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL371177 | 0.78 | MAPT (0.55) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251657-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | Sun Pharmaceutical Industries Limited (IN) | 2017-12-06 | — | — | EP | claimed |
| US-20170340649-A1 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-30 | — | — | US | claimed |
| EP-0996418-B2 | DERMATOLOGICAL COMPOSITIONS | RECKITT & COLMAN OVERSEAS (GB) | 2009-04-08 | — | — | EP | claimed |
| US-20080119527-A1 | Composition for combating the localized hyperpigmentation of dark skin | L'OREAL (FR) | 2008-05-22 | — | — | US | claimed |
| EP-1133979-B1 | Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon | OREAL (FR) | 2005-10-26 | — | — | EP | claimed |
| EP-1129694-B1 | Use of components for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon | OREAL (FR) | 2005-09-07 | — | — | EP | claimed |
| EP-0996418-B1 | DERMATOLOGICAL COMPOSITIONS | BOOTS CO PLC (GB) | 2004-05-12 | — | — | EP | claimed |
| US-20040047885-A1 | Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | L'OREAL | 2004-03-11 | — | — | US | claimed |
| US-20020155962-A1 | Nonaqueous hair styling composition and method of use | ANDREW JERGENS COMPANY, THE | 2002-10-24 | — | — | US | claimed |
| US-20010051170-A1 | Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | L'OREAL (FR) | 2001-12-13 | — | — | US | claimed |
| US-20010018060-A1 | Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | L'OREAL (FR) | 2001-08-30 | — | — | US | claimed |
| EP-0996418-A1 | DERMATOLOGICAL COMPOSITIONS | The Boots Company PLC (GB) | 2000-05-03 | — | — | EP | claimed |
| WO-1999011237-A9 | DERMATOLOGICAL COMPOSITIONS | BOOTS CO PLC (GB) | 2000-04-06 | — | — | WO | claimed |
| WO-1999011237-A1 | DERMATOLOGICAL COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 1999-03-11 | — | — | WO | claimed |
| US-12582715-B1 | Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis | CREIGHTON UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250339360-A1 | COSMETIC COMPOSITIONS COMPRISING RETINOIDS AND MOISTURIZERS AND METHODS FOR STABLIZING RETINOIDS | ELC MANAGEMENT LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250042940-A1 | 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT | CREIGHTON UNIV (US) | 2025-02-06 | — | — | US | disclosed |
| US-5744062-A | CONTROLLING VISCOSITY | R.I.T.A. CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1998008597-A1 | EMULSIFIER BLENDS FOR OIL-IN-WATER EMULSIONS | R.I.T.A. CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0534823-B1 | Anhydrous make-up composition containing a fatty phase and the process for cosmetic use of this composition | OREAL (FR) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582715-B1 | Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis | EPCAM, ROS1, DCX | MAPT 2628/4885MAPK1 447/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.